McLaren Cancer Institute - Port Huron(1.4 mi away)Contact
+103 other location
prostate specific antigen
luteinizing hormone-releasing hormone agonist
recurrent prostate cancer
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive
disease features will receive salvage radiation therapy and standard androgen deprivation
therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free
survival when enhanced ADT is used compared to standard ADT.
To determine whether, in men with post-prostatectomy PSA (prostate specific antigen)
recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced
androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog,
will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.